Assistant Professor of Medicine, University of Chicago Medicine
Oncology
Dr. Blase N. Polite, MD
|
|
Give Review
Blase N. Polite works in the field of Oncology. He went to medical school at Indiana University School of Medicine. Indiana University School of Medicine is ranked 45/47 in Research/PrimaryCare. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Blase Polite is also published. He has 33 publications published. The lastest publication: "Oncology Pathways-Preventing a Good Idea From Going Bad.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon Cancer patients: NCCTG N0147 (Alliance).
- Oncology Pathways-Preventing a Good Idea From Going Bad.
- Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
- Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.
- American Society of Clinical Oncology Policy Statement on Medicaid Reform.
- Metformin for primary colorectal Cancer prevention in patients with diabetes: A case-control study in a US population.
- The Role of Statins for Primary Prevention in Non-elderly Colorectal Cancer Patients.
- Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies.
- Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- The vulnerable elders survey-13 predicts mortality in older adults with later-stage colorectal Cancer receiving chemotherapy: a prospective pilot study.
- Unsupported off-label chemotherapy in metastatic colon Cancer.
- Infused chemotherapy use in the elderly after patent expiration.
- Phase II, Open-label Study of Brivanib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.
- Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution.
- Race and subset Analyses in clinical trials: time to get serious about data integration.
- American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities.
- Exploring racial differences in outcome and treatment for metastatic colorectal Cancer: Results from a large prospective observational cohort study (BRiTE).
- Dasatinib in previously treated metastatic colorectal Cancer: a phase II trial of the University of Chicago Phase II Consortium.
- Predictors of competing mortality in early breast Cancer.
- Predictors of competing mortality in advanced head and neck Cancer.
- Triple-negative breast Cancers: a view from 10,000 feet.
- Racial differences in clinical outcomes from metastatic breast Cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
- Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon Cancer.
- Colorectal Cancer model of health disparities: understanding mortality differences in minority populations.
- Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell Carcinoma: results of a s...
- Are venous thromboembolic events associated with subsequent breast and coloRectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries.
- Colorectal Cancer and race: understanding the differences in outcomes between African Americans and whites.
- Breast Cancer and race: a rising tide does not lift all boats equally.
- Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast Cancer.
- Personalized colon Cancer care in 2010.
- Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic coloRectal carcinoma.
- Value-based insurance design in oncology.
Schools
Indiana University School of Medicine
University Of Chicago Hosps
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Coventry Health Care
- Health and Life PPO
- Platinum PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Pipefitters
- Priority Health
- Sagamore Plus
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
Indiana University School of Medicine
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1306873211 | |
| NPPES Provider LastName | POLITE | |
| NPPES Provider FirstName | BLASE | |
| NPPES Provider ZIPCode | 60637 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 160.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 8.13 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306873211 |
| Last Name Of The Provider | POLITE |
| First Name Of The Provider | BLASE |
| View All |
Similar Doctors
|
|
Dr. Stephanie B. Tsai, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Divyesh G. Mehta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Gradishar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julia B. Ashenhurst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syed S. Hassan, MD |
|
|
Dr. Katherine A. Bueschel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nyambi Ebie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander C. Minella, MD |